Upcoming Conference Call for INmune Bio Inc.
INmune Bio Inc. (NASDAQ: INMB), a pioneering clinical-stage biotechnology company known for its innovative approaches to treating Alzheimer’s Disease through neuroinflammation research, is set to host a conference call soon. This event aims to discuss its financial results for the first quarter of 2025, alongside important corporate developments.
Call Details for Shareholders
Investors and interested parties are encouraged to join the call, scheduled for May 8, 2025, at 4:30 PM EDT. Participants should dial in 5 to 10 minutes prior to the start time and mention the INmune Bio First Quarter Conference Call when prompted by the operator.
Accessing the Live Webcast
For those unable to attend the call, a live audio webcast will be made available. This can be accessed through their official website shortly before the scheduled time, ensuring that everyone can stay informed about INmune Bio’s progress and updates.
About INmune Bio Inc.
Based in Boca Raton, Florida, INmune Bio Inc. is at the forefront of clinical research with a focus on therapies that harness the body's innate immune system to combat various diseases. The company has developed three main product platforms. One of them, the Dominant-Negative Tumor Necrosis Factor (DN-TNF), is designed to neutralize soluble TNF, addressing its role in immune dysfunction. This platform is currently undergoing clinical trials to assess its efficacy in treating Mild Alzheimer’s disease, Mild Cognitive Impairment, and treatment-resistant depression.
Innovations in Immunology
Another platform, the Natural Killer Cell Priming Platform, includes the development of INKmune®, which primes a patient’s natural killer cells to help eradicate cancer-related minimal residual disease. This treatment is currently being evaluated in trials focusing on metastatic castration-resistant prostate cancer.
The third innovative approach is CORDStrom™, a novel platform based on human umbilical cord-derived mesenchymal Stromal/Stem cells. This program has recently completed a blinded randomized trial aimed at addressing recessive dystrophic epidermolysis bullosa, highlighting the significant potential of INmune Bio’s offerings.
Understanding INmune Bio's Mission
INmune Bio is dedicated to employing precision medicine to tackle diseases driven by chronic inflammation and oncology. The pursuit of developing transformative therapies that can positively impact patients’ lives showcases their commitment to advancing healthcare solutions. As they work towards this mission, maintaining open communication with stakeholders remains a priority.
Contacting INmune Bio Inc.
For further inquiries or to understand more about their advancements, you can reach out directly to their contact points. David Moss, the CFO, is available at (561) 710-0512 or via email at info@inmunebio.com. Additionally, Daniel Carlson, the Head of Investor Relations, is also accessible for any investor-related questions at (415) 509-4590 or dcarlson@inmunebio.com.
Frequently Asked Questions
What is the purpose of the upcoming call?
The call is intended to discuss INmune Bio's financial results and provide an update on the company's progress and initiatives.
When will the conference call take place?
The conference call is scheduled for May 8, 2025, at 4:30 PM EDT.
How can I access the conference call?
Participants can dial in by following the provided instructions or access the live audio webcast through the INmune Bio website.
What are the main product platforms of INmune Bio?
INmune Bio has three key platforms focused on treating conditions related to inflammation, cancer, and neurodegeneration, namely DN-TNF, INKmune®, and CORDStrom™.
Who can I contact for more information?
Contact David Moss or Daniel Carlson for inquiries related to the company or investments at the provided emails and phone numbers.
